Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Brief description of study
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Clinical Study Identifier: s23-00360
ClinicalTrials.gov Identifier: NCT05732831
Principal Investigator:
Salman Rafi Punekar.
Other Investigators:
Nila Theresa De La Rosa,
Scot Niglio,
Samantha VanMaanen,
Eneil De La Pena,
Jessica Wang,
Kathleen M Madden,
Elaine Shum,
Kristen Spencer,
Joshua K Sabari,
Keriann M Scavone,
Vamsidhar Velcheti,
Nina Beri,
Nancy Chan,
Caitlin Elizabeth Ryan,
Kirby Rodriguez,
Janice Mehnert,
Douglas K Marks.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.